Open Access<p>An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug–Drug Interaction Study</p>
Author(s) -
Qiong Wang,
Zhe Chen,
Dingwen Chen,
Xia-yan Ye
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
ISSN - 1177-8881
DOI - 10.2147/dddt.s243760
Subject(s) - itraconazole , chemistry , chromatography , pharmacokinetics , bioanalysis , analyte , liquid chromatography–mass spectrometry , fluconazole , pharmacology , mass spectrometry , medicine , antifungal , dermatology
Gilteritinib, a novel, potent FLT3/AXL inhibitor, was recently approved in Japan and USA for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.